Please login to the form below

Not currently logged in
Email:
Password:

Rapidscan/GE Healthcare distribution deal

Rapidscan choses GE Healthcare to distribute coronary artery disease treatment in the UK and Germany

Rapidscan Pharma Solutions EU (RPS) has come to an agreement with GE Healthcare to promote and distribute Rapiscan (regadenoson) in the UK and Germany.

Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging in adult patients unable to undergo adequate exercise stress in the diagnosis of coronary artery disease (CAD).

Rapiscan is administered as a non-weight based bolus injection and is the first and only selective A2A adenosine receptor agonist to have a licence for use in this indication. 

Stephen Lightfoot, global MI-SPECT segment leader, Medical Diagnostics, GE Healthcare, said: "The opportunity to launch Rapiscan with Rapidscan Pharma Solutions EU leverages the expertise and unique capabilities of both organisations - to bring an important product used for the diagnosis of coronary artery disease to the UK and German marketplace."  

Regadenoson was launched in the US in 2008 following clinical trials of more than 2,000 patients with known or suspected CAD.

12th May 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

A leading global patient-activation group - comprising of a digital insight consultancy, creative activation agency. Our foundations lie in behavioural...

Latest intelligence

Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...
InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...

Infographics